Loading...
•
Mar 31, 2024
Immunocore Q1 2024 Earnings Report
Immunocore's financial position and operational performance for Q1 2024 were detailed. KIMMTRAK sales increased, and clinical trials for brenetafusp and other candidates progressed.
Key Takeaways
Immunocore reported a 36% increase in KIMMTRAK net product revenue, reaching $70.3 million in Q1 2024. The company continues to expand global access and advance clinical trials for its pipeline candidates, including brenetafusp. Net loss for the quarter was $24.4 million, and cash and cash equivalents stood at $832.8 million.
KIMMTRAK net revenues reached $70.3 million, a 36% increase year-over-year.
KIMMTRAK was launched in 7 additional countries, expanding global access.
Phase 1/2 clinical data for brenetafusp in late-line cutaneous melanoma was selected for oral presentation at ASCO 2024.
First patient randomization in the PRISM-MEL-301 trial is expected in Q2 2024.
Revenue by Segment
Forward Guidance
Immunocore anticipates continued progress in its clinical trials and expansion of KIMMTRAK availability.
Positive Outlook
- Randomization of first patient in PRISM-MEL-301 expected in Q2 2024.
- Additional clinical data from brenetafusp trials expected throughout 2024.
- IND or CTA submissions for IMC-P115C by mid-2024 and for IMC-T119C in Q4 2024 remain on track.
- Phase 1 clinical trial for IMC-R117C expected to start in the second half of 2024.
- MAD data for IMC-M113V expected to be presented in the second half of 2024.
Challenges Ahead
- Worsening macroeconomic conditions could impact the company's business.
- Potential delays in clinical trials due to patient enrollment or other factors.
- Unexpected safety or efficacy data observed during preclinical studies or clinical trials.
- Actions by regulatory agencies may affect the initiation, timing, and progress of clinical trials.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...